Binding agreement of investment in and acquisition of IOPtima

Tel Aviv (November 21, 2017)  – BioLight is pleased to announce that together with the other shareholders of its subsidiary IOPtima Ltd., it has entered into a binding agreement for the investment in and the acquisition in stages of IOPtima by the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co. Pending closings pre conditions, the investment in and acquisition in stages of IOPtima will be executed in four separate stages, whereby the first stage will include a direct investment into IOPtima by Chengdu Kanghong Pharmaceutical Group Co for a total consideration of about US$7 million at a pre-money valuation of $30 million, and the following stages will include an acquisition of the remaining IOPtima shares from all its other shareholders (including BioLight). In the event that the transaction will be fully executed, the gross consideration to BioLight is expected to range between approximately US$23 million and approximately US$27.3 million.

Link to the complete article

Link to Newsroom

Comments are closed.